180913-13-7

Upstream product

• 57455-06-8 3-iodobenzylalcohol 
• 292638-85-8 acrylic acid methyl ester 
• 15852-73-0 (3-Bromophenyl)methanol 

Downstream Products

• 62876-43-1 methyl 3-(3-(hydroxymethyl)phenyl)propanoate 
• 1018674-39-9 (2E)-3-(3-formylphenyl)-N-[1-(2-methylpropoxy)ethoxy]prop-2-enamide 
• 1018674-38-8 (2E)-3-[3-(hydroxymethyl)phenyl]-N-[1-(2-methylpropoxy)ethoxy]prop-2-enamide 

Relevant academic research and scientific papers

Synthetic Posttranslational Modifications: Chemical Catalyst-Driven Regioselective Histone Acylation of Native Chromatin

Posttranslational modifications (PTMs) of histones play an important role in the complex regulatory mechanisms governing gene transcription, and their dysregulation can cause diseases such as cancer. The lack of methods for site-selectively modifying nati

HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE

The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.

ALPHA, ALPHA - DI SUBSTITUTED GLYCINE ESTER DERIVATIVES AND THEIR USE AS HDAC INHIBITORS

Compounds selected from the following group and their salts are inhibitors of HDAC activity, useful in the treatment of, inter alia, cell proliferative disease and inflammation: Cyclopentyl 1 -[({5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]pyridin-2- yl}methy)amino]cyclopropanecarboxylate; Cyclopentyl 1 -[({5-[(1E)-3-(hydroxyamino)-3- oxoprop-1-en-1-yl]pyridin-2-yl}methy)amino]cyclobutanecarboxylate; Cyclopentyl 1-[({5- [(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]pyridin-2yl}methyl)amino]- cyclopentanecarboxylate; Cyclopentyl 1-[({5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1- yl]pyridin-2-yl}methyl)amino]cyclohexanecarboxylate; Cyclopentyl 4-[({5-[(1E)-3- (hydroxyamino)-3-oxoprop-1 -en-1 -yl]pyridin-2-yl}methyl)amino]tetrahydro-2H-pyran-4- carboxylate; Cyclopentyl 4-[({6-[(1E)-3-{[1 -(2-methylpropoxy)ethoxy]amino}-3-oxoprop-1 - en-1 -yl]pyridin-3-yl}methyl)amino]tetrahydro-2H-pyran-4-carboxylate; Cyclopentyl 1 -({4- [(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2-methylbenzyl}amino)- cyclohexanecarboxylate; Cyclopentyl 1-({4-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]- 2-methylbenzyl}amino)cyclopentanecarboxylate; Cyclopentyl 1-({4-[(1E)-3- (hydroxyamino)-3-oxoprop-1-en-1-yl]-2-methylbenzyl}amino)cyclobutanecarboxylate; Methylcyclopentyl 4-[({6-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]pyridin-3- yl}methyl)amino]tetrahydro-2H-pyran-4-carboxylate; Cyclopentyl 4-{[1 -({6-[(1E)-3- (hydroxyamino)-3-oxoprop-1-en-1-yl]pyridin-3-yl}methyl)piperidin-4-yl]amino}tetrahydro- 2H-pyran-4-carboxylate; Cyclopentyl 4-{[1-({5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1- yl]pyridin-2-yl}methyl)piperidin-4-yl]amino}tetrahydro-2H-pyran-4-carboxylate; Cyclopentyl 4-({4-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]benzyl}amino)tetrahydro- 2H-pyran-4-carboxylate; Cyclopentyl 4-({3-[(1E)-3-(hydroxyamino)-3-oxoprop-1 -en-1 - yl]benzyl}amino)tetrahydro-2H-pyran-4-carboxylate; and (3R)-Tetrahydrofuran-3-yl N-{4- [(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]benzyl}-2-methyl-D-leucinate.

THERAPEUTIC SUBSTITUTED CYCLOPENTANES

Therapeutic compounds are disclosed herein. Methods, compositions, and medicaments related thereto are also disclosed. The compounds described herein are used to treat ocular conditions, bowel disease and baldness.

HDAC INHIBITORS

Compounds of formula (I) inhibit HDAC activity, wherein A, B and D independently represent =C- or =N-; W is a divalent radical -CH=CH- or CH2CH2-; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; z is 0 or 1; and Y, L1, and X1 are as defined in the claims.

Therapeutic Substituted Cyclopentanes

Therapeutic compounds are disclosed herein. ???????????

12-ARYL PROSTAGLANDIN ANALOGS

Compounds comprising the formula (I) are disclosed, wherein Y, A, X, R, D, and n are as described. A compound comprising a prostaglandin EP2 selective agonist wherein the ω-chain comprises a substituted phenyl, wherein at least one substituent